Core--Virology Facility

$160,692P01FY2005AINIH

University Of Iowa, Iowa City IA

Investigators

Linked publications & trials

Paper 39205188 Paper 39194251 Paper 39005257 Paper 38895461 Paper 38895239 Paper 38888344 Paper 38744813 Paper 38486021 Paper 38392560 Paper 38168680 Paper 38126789 Paper 38105421 Paper 38102143 Paper 38076875 Paper 37882568 Paper 37781614 Paper 37698016 Paper 37624979 Paper 37623322 Paper 37607224 Paper 37487098 Paper 37382441 Paper 37311762 Paper 37066301 Paper 36625656 Paper 36378534 Paper 36121829 Paper 35893821 Paper 35643533 Paper 35594398 Paper 35588276 Paper 35579391 Paper 35499307 Paper 35477024 Paper 35361968 Paper 35314834 Paper 35229638 Paper 35073761 Paper 35062015 Paper 35059374 Paper 34981044 Paper 34909775 Paper 34837062 Paper 34756886 Paper 34686605 Paper 34517762 Paper 34340553 Paper 34340537 Paper 34289058 Paper 34229775 Paper 34213885 Paper 34210738 Paper 34103714 Paper 34099556 Paper 34022154 Paper 33989113 Paper 33918600 Paper 33907749 Paper 33901166 Paper 33900908 Paper 33844653 Paper 33752131 Paper 33653888 Paper 33453811 Paper 33377063 Paper 33277988 Paper 33216734 Paper 33166988 Paper 33144319 Paper 33085654 Paper 33051211 Paper 33035475 Paper 32971472 Paper 32967005 Paper 32833200 Paper 32807916 Paper 32783787 Paper 32747425 Paper 32717182 Paper 32704094 Paper 32643603 Paper 32634129 Paper 32629393 Paper 32577664 Paper 32553273 Paper 32511303 Paper 32507409 Paper 32265331 Paper 32218786 Paper 32173256 Paper 32145185 Paper 32123347 Paper 32087122 Paper 32047128 Paper 31978944 Paper 31883097 Paper 31883095 Paper 31883084 Paper 31742530 Paper 31355779

Abstract

The Virology Core will have several functions that will be critical for success of this PO1 Grant. It will grow and titer wild type SARS-CoV and HCoV-OC43. It will develop recombinant SARS-CoV, HCoV-OC43, MHV, adenovirus, influenza A and respiratory syncytial virus. These viruses will be used by all investigators in the Program, both at the University of Iowa and Loyola University Medical Center, to probe factors involved in SARS-CoV pathogenesis. The Core will teach members of the Project the methods important for recombinant virus production, as well as provide a service function. Personnel working in the Core are experienced in virological and cell culture techniques and have also been trained to work in our BSL3 laboratory, since it will be necessary to propagate some of the recombinant viruses under these more stringent conditions. The Core will efficiently provide reagents for the Program investigators, thereby allowing them to focus on issues related to the pathogenesis of SARS-CoV.

View original record on NIH RePORTER →